Tapestry Pharmaceuticals, Inc., together with its subsidiaries, develops therapies for the treatment of cancer. Its development stages therapeutic candidate products include TPI 287 IV, a Phase I product for prostate, nonsmall cell lung, and breast cancers; TPI 287 oral formulation, a preclinical development stage product for prostate, nonsmall cell lung, pancreatic, ovarian, breast, and colon cancers. The company’s development stages products also comprise Quassinoids and Linked Cytotoxics, preclinical development stage products for Cancers. Tapestry Pharmaceuticals was founded in 1991 and is based in Boulder, Colorado.